# The Efficacy and Safety of IBI363 in Solid Tumors

> **NCT06081907** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 430 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** IBI363
- **DRUG:** IBI363
- **DRUG:** IBI363
- **DRUG:** IBI363
- **DRUG:** IBI363

## Key facts

- **NCT ID:** NCT06081907
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-25
- **Primary completion:** 2026-12-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2024-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06081907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06081907, "The Efficacy and Safety of IBI363 in Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06081907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*